PolyPeptide Group AG
SIX:PPGN
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
14.19
34.4
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CHF.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
PolyPeptide Group AG
PolyPeptide Group AG
Research & Development
PolyPeptide Group AG
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
PolyPeptide Group AG
SIX:PPGN
|
Research & Development
-€1.5m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
35%
|
CAGR 10-Years
N/A
|
|
|
Bachem Holding AG
SIX:BANB
|
Research & Development
-CHf12.6m
|
CAGR 3-Years
-54%
|
CAGR 5-Years
-48%
|
CAGR 10-Years
-19%
|
|
|
Siegfried Holding AG
SIX:SFZN
|
Research & Development
-CHf43.3m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
|
|
Lonza Group AG
SIX:LONN
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Tecan Group AG
SIX:TECN
|
Research & Development
-CHf64.1m
|
CAGR 3-Years
2%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
N/A
|
|
|
SKAN Group AG
SIX:SKAN
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
PolyPeptide Group AG
Glance View
PolyPeptide Group AG is a contract development and manufacturing organization for clinical and approved commercial-stage peptide drug substances used in peptide-based therapeutics. The company is headquartered in Zug, Zug and currently employs 1,041 full-time employees. The company went IPO on 2021-04-29.
See Also
What is PolyPeptide Group AG's Research & Development?
Research & Development
-1.5m
EUR
Based on the financial report for Dec 31, 2023, PolyPeptide Group AG's Research & Development amounts to -1.5m EUR.
What is PolyPeptide Group AG's Research & Development growth rate?
Research & Development CAGR 5Y
35%
Over the last year, the Research & Development growth was -18%. The average annual Research & Development growth rates for PolyPeptide Group AG have been -4% over the past three years , 35% over the past five years .
You don't have any saved screeners yet
